U.S. Antibiotic Resistance Market Size & Outlook
U.S. antibiotic resistance market, 2018-2030 (US$M)
Related Markets
U.S. antibiotic resistance market highlights
- The U.S. antibiotic resistance market generated a revenue of USD 2,964.6 million in 2023 and is expected to reach USD 4,194.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.1% from 2024 to 2030.
- In terms of segment, cuti was the largest revenue generating disease in 2023.
- CDI is the most lucrative disease segment registering the fastest growth during the forecast period.
Antibiotic resistance market data book summary
| Market revenue in 2023 | USD 2,964.6 million |
| Market revenue in 2030 | USD 4,194.4 million |
| Growth rate | 5.1% (CAGR from 2023 to 2030) |
| Largest segment | Cuti |
| Fastest growing segment | CDI |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CUTI, CDI, ABSSSI, HABP, CABP, CIAI, BSI |
| Key market players worldwide | Melinta Therapeutics, Basilea Pharmaceutica Ltd, Theravance Biopharma Inc, Seres Therapeutics Inc, AbbVie Inc, Merck & Co Inc, Hubsan, Wockhardt, Entasis Therapeutics, Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Axogen Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.0% of the global antibiotic resistance market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antibiotic resistance market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 391.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibiotic Resistance Market Scope
Antibiotic Resistance Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. antibiotic resistance market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antibiotic resistance market will help companies and investors design strategic landscapes.
Cuti was the largest segment with a revenue share of 23.12% in 2023. Horizon Databook has segmented the U.S. antibiotic resistance market based on cuti, cdi, absssi, habp, cabp, ciai, bsi covering the revenue growth of each sub-segment from 2018 to 2030.
- U.S. Antibiotic Resistance Disease Outlook (Revenue, USD Million, 2018-2030)
- cUTI
- CDI
- ABSSSI
- HABP
- CABP
- cIAI
- BSI
- U.S. Antibiotic Resistance Pathogen Outlook (Revenue, USD Million, 2018-2030)
- E.coli
- klebsiella pneumoniae
- P. aeruginosa
- S. aureus
- A. baumannii
- Strep. Pneumoniae
- H. influenzae
- CDI
- Enterococcus fecium
- U.S. Antibiotic Resistance Drug Class Outlook (Revenue, USD Million, 2018-2030)
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Combination therapies
- Cephalosporins
- Other drug classes
- U.S. Antibiotic Resistance Mechanism of Action Outlook (Revenue, USD Million, 2018-2030)
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Other mechanism of actions
- U.S. Antibiotic Resistance Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Reasons to subscribe to U.S. antibiotic resistance market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. antibiotic resistance market databook
-
Our clientele includes a mix of antibiotic resistance market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. antibiotic resistance market , including forecasts for subscribers. This country databook contains high-level insights into U.S. antibiotic resistance market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. antibiotic resistance market size, by disease, 2018-2030 (US$M)
U.S. Antibiotic Resistance Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
